AI-generated summary
This review examines how photobiomodulation, which applies low-level red or near-infrared light, has been used for diabetes and its complications, along with the proposed mechanisms and advantages and disadvantages. The authors state that PBM has been shown to be efficacious for a wide range of organ damage and aim to generate new ideas for its use in diabetes. The abstract does not report pooled results or specific effect sizes.
- Who or what was studied
- Patients with diabetes mellitus and its complications, including diabetic retinopathy, diabetic foot ulcers, diabetic peripheral neuropathy and diabetic periodontitis
- Limits stated in the abstract
- The abstract does not state the number of studies reviewed or report quantitative efficacy results, so the strength of the evidence cannot be judged from it.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Near-infrared, Neuropathy, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.